AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00361881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Dose 5 times daily for 5 days
Study NCT01603303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
Study NCT01603303 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
Study NCT01603303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials
Description: Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
Study NCT01603303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education Materials
Description: Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
Study NCT01603303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luvena
Description: Use vaginally 2 or 3 times a week.
Study NCT01603303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyalo-Gyn
Description: Use vaginally 2 - 3 times a week.
Study NCT01603303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal Lubricant
Description: Water-based vaginal lubricant used during sexual activity.
Study NCT01603303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Internet-Based Website
Description: Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
Study NCT01603303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling.
Description: Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
Study NCT00569140 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: E10030
Description: Intravitreal injection
Study NCT01163526 — intervention group
Intervention type: PROCEDURE
Intervention: CT perfusion
Study NCT02537717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sapphire Lens
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study NCT02537717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Each subject randomized to wear either the test or control in either the left of right eye.
Study NCT03471312 — intervention group
Intervention type: DRUG
Intervention: Magnesium
Description: magnesium therapy
Study NCT02598284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Care
Description: Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
Study NCT02598284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Population Management
Description: Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program.
Study NCT02033434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Description: Atomized Intranasal Ketamine, 50mg
Study NCT02186275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day
Description: * Weight at inclusion \< 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~* Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.
Study NCT02186275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 800 UI/day then 800 UI/day
Description: * Weight \< 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~* Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance
Study NCT01740713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone, dose level 1
Description: a solution at 80 mg/mL will be administered orally
Study NCT01740713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone, dose level 2
Description: a solution at 80 mg/mL will be administered orally
Study NCT01740713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone, dose level 3
Description: a solution at 80 mg/mL will be administered orally
Study NCT03267550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SceneRay wireless and remote DBS system
Description: Implement therapeutic programming in patients with network coverage at home
Study NCT00966511 — intervention group
Intervention type: PROCEDURE
Intervention: Lung resection surgery
Description: The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
Study NCT06726694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: class II molar relation correction by advanced molar distalization appliance
Description: correction of class II molar relation by a novel miniscrews distalizer
Study NCT01065038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide
Study NCT01065038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Study NCT04933071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Podcast
Description: A list of podcasts that are specified for each rotation
Study NCT04437485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Good Days Ahead (GDA)
Description: GDA (Empower Interactive) is an empirically supported, HIPAA compliant, computerized CBT for depression appropriate for primary care patients and people with little computer experience. GDA uses an interactive, multimedia format to deliver 9 45-minute sessions, the structure and content of which mirror face-to-face CBT. General topics include identifying and modifying automatic thoughts, using behavioral activation and other behavioral methods, identifying and modifying schemas, using effective coping strategies, and employing other core CBT methods. GDA is empirically supported - it is acceptable to patients, achieves superior depression outcomes to waitlist comparators, and yields equivalent (noninferior) depression outcomes to standard face-to-face CBT. To minimize time/transportation barriers, GDA sessions occur at the PI's lab or a location with internet access selected by the patient (patient's, family member's, or friend's home).
Study NCT04437485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment in Primary Care (PST-PC)
Description: PST-PC is an established, manualized, empirically supported CBT developed for primary care. During the 6-10 30-minute sessions, patients are taught skills for solving problems contributing to depression. We will deliver PST-PC by phone, which has been found to be feasible and efficacious.
Study NCT04437485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Medications
Description: We first considered all FDA-approved antidepressants and excluded those with weight gain effects (tricyclics, paroxetine, mirtazapine) and those rarely used in primary care (MAOIs). Then, we used existing evidence to inform the structure. We made bupropion (an aminoketone) and fluoxetine (an SSRI) our first-line and second-line antidepressants, as meta-analyses indicate that their use is associated with weight loss. We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight. Our team will make recommendations to the patient's PCP, who will write prescriptions. Our team and the PCP will then collaboratively manage pharmacotherapy.
Study NCT04437485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: (1) The graduate research assistant (RA) will have a 50-minute call with AC patients to review depression materials. The RA will provide a list of Eskenazi Health mental health services and will encourage patients to follow-up with their PCP. We will then send an electronic health record message to the PCP encouraging them to address their patient's depression, note that there are no care restrictions, and provide the same list of services. (2) The RA will call AC patients every 4 weeks to assess depressive symptoms and will notify clinical staff to encourage additional care when indicated. (3) AC patients will receive current primary care for depression. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
Study NCT00248482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
Study NCT00248482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec™
Description: Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
Study NCT01064115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride
Description: Cetirizine Hydrochloride Tablets 10 mg
Study NCT01064115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine Hydrochloride
Description: Cetirizine Hydrochloride Tablets 10 mg
Study NCT00248482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles
Study NCT01885221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia Support Intervention
Study NCT00544375 — intervention group
Intervention type: DEVICE
Intervention: Optical measurement
Description: Optical measurement neonatal tissues
Study NCT04013048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Fluzoparib
Description: Patients will receive single dose of orally \[14C\]- Fluzoparib on Day 1.
Study NCT01365286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine (Procoralan)
Description: Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
Study NCT01365286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
Study NCT02697266 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study.
Study NCT00809900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Experimental
Description: Administration of of 480 mL cranberry juice
Study NCT04101552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket shield technique with xenophobic graft particulate and without the use of graft
Description: the jumping gap between the implant and the shield is grafted by xenograft particulate and the control group is not grafted
Study NCT02237443 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rocuronium
Description: Administration of a NMBD
Study NCT02237443 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vecuronium Bromide
Description: Administration of a NMBD
Study NCT01202266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05161704 or Placebo
Description: PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
Study NCT02237443 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Succinylcholine
Description: Administration of a NMBD
Study NCT02736461 — intervention group
Intervention type: PROCEDURE
Intervention: Floor repair surgery
Study NCT01202266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05161704 or Placebo
Description: PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
Study NCT01202266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05161704 or Placebo
Description: PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
Study NCT01843127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Study NCT02205671 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Better Caregivers Small-group Workshop
Study NCT04012541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: active dental procedure
Description: scaling and root planing
Study NCT04012541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: post-myocardial infarction management
Description: aspirin, clopidogrel, ticagrelor
Study NCT04012541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: post-myocardial infarction management
Description: aspirin, clopidogrel, ticagrelor
Study NCT04012541 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: basic periodontal examinations
Description: panorama radiograph : full mouth periapical radiograph
Study NCT04012541 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: basic periodontal examinations
Description: panorama radiograph : full mouth periapical radiograph
Study NCT05577338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Theory of Mind psychotherapy
Description: a semi-structured, multidomain, tailored group psychotherapy
Study NCT05577338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: disease-related health knowledge
Study NCT02289495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2838232
Description: GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
Study NCT02289495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
Study NCT02289495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
Study NCT02614729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)
Description: Diet contains all plant proteins. Meals are evenly distributed throughout the day.
Study NCT02614729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)
Description: Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
Study NCT02614729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein-Beef, Even Distribution (HP-BEEF-EVEN)
Description: Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
Study NCT02614729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)
Description: Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
Study NCT05006235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine Inhalation Solution
Study NCT01843127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01843127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Study NCT05006235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Study NCT05006235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Inhalants
Study NCT03271424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oraquick HIV Self Test - Choice
Description: This is an oral swab in home HIV test.
Study NCT03271424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Atomo HIV Self Test - Choice
Description: This is a blood finger prick in home HIV test.
Study NCT03271424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oraquick HIV Self Test and Atomo HIV Self Test - Both
Description: This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
Study NCT01487135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EVP-6124
Description: A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
Study NCT01487135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
Study NCT01487135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: A moxifloxacin 400 mg tablet administered orally on Day 1
Study NCT04974255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measuring of fibrosis in thyroid specimen and measuring of Anti-tTG in serum samples
Description: Examination of pathology specimen and laboratory measuring
Study NCT00972192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient HIV testing
Description: Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
Study NCT00972192 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Outpatient HIV testing
Description: Participants randomised to the control arm received referral for testing post-discharge
Study NCT01733537 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free reflective, fluorescent vest
Description: Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
Study NCT01733537 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Both arms will receive brief, basic education about recommended measures to increase their visibility
Study NCT01480622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF tablets
Description: White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331
Study NCT02963454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microdialysis Probe (Muscle microdialysis)
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.
Study NCT02963454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis Probe (Muscle microdialysis)
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply.
Study NCT02963454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine (5 μg/kg/min) will be used as indicated
Study NCT01733537 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Both arms will receive brief, basic education about recommended measures to increase their visibility